<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41031479</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Drug-Coated Balloon Versus Drug-Eluting Stent for De Novo Lesions of Large Coronary Arteries: A Systematic Review and Meta-Analysis of Angiographic and Clinical Outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.70223</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efficacy of drug-coated balloons (DCBs) has been established in the treatment of in-stent restenosis and small vessel coronary artery disease, while utility in large-vessel de novo lesions remains controversial.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We sought to study the angiographic and clinical outcomes after treatment of large vessel de novo coronary lesions with DCB versus drug-eluting stent (DES).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched electronic databases through March 2025 for relevant studies. Outcomes were compared using random effects modeling for summary estimates. We performed subgroup analyses by study design.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our analysis included 16 studies (eight randomized controlled trials and eight observational) with 9745 patients. Follow-up duration was 17&#x2009;&#xb1;&#x2009;8 months for DCB and 16&#x2009;&#xb1;&#x2009;4 months for DES. While acute gain was significantly lower with DCB (MD&#x2009;=&#x2009;-0.45, 95% CI: -0.63 to -0.26; p&#x2009;&lt;&#x2009;0.00001; I&#xb2;&#x2009;=&#x2009;74%), no significant differences were observed in late lumen loss (MD&#x2009;=&#x2009;-0.03, 95% CI: -0.09 to 0.04; p&#x2009;=&#x2009;0.47; I&#xb2; = 47%) or binary restenosis (RR&#x2009;=&#x2009;2.22, 95% CI: 0.94 to 5.24; p&#x2009;=&#x2009;0.07; I&#xb2; = 13%). Clinically, there was no significant difference between DCB and DES in target lesion failure and overall major adverse cardiac events, and this was consistent regardless of the study design (randomized vs. observational).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compared with DES, treatment with DCB yields a less optimal immediate angiographic result but comparable clinical outcomes in patients with de novo lesions of large coronary arteries.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Suez Medical Complex, Ministry of Health and Population, Suez, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansour</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkasaby</LastName><ForeName>Mohamed Hamouda</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadan</LastName><ForeName>Shrouk</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6776-883X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabil</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9605-1539</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwannasom</LastName><ForeName>Pannipa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2280-8030</Identifier><AffiliationInfo><Affiliation>Lifespan Cardiovascular Institute and Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Winter</LastName><ForeName>Robbert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Cardiology Department, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemetsberger</LastName><ForeName>Rayyan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelghani</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6949-8749</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Unit, Department of Internal Medicine, Sohar Hospital, Sohar, Oman.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug&#x2010;coated balloon</Keyword><Keyword MajorTopicYN="N">drug&#x2010;eluting stent</Keyword><Keyword MajorTopicYN="N">large de novo coronary artery lesions</Keyword><Keyword MajorTopicYN="N">meta&#x2010;analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031479</ArticleId><ArticleId IdType="doi">10.1002/ccd.70223</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Hassan, A. M. Amin, A. F. Gadelmawla, et al., &#x201c;Comparative Effectiveness of Ultrathin vs. Standard Strut Drug&#x2010;Eluting Stents: Insights From a Large&#x2010;Scale Meta&#x2010;Analysis With Extended Follow&#x2010;Up,&#x201d; European Journal of Medical Research 29, no. 1 (July 2024): 388.</Citation></Reference><Reference><Citation>M. V. Madhavan, A. J. Kirtane, B. Redfors, et al., &#x201c;Stent&#x2010;Related Adverse Events &gt;&#x2009;1 Year After Percutaneous Coronary Intervention,&#x201d; Journal of the American College of Cardiology 75, no. 6 (February 2020): 590&#x2013;604.</Citation></Reference><Reference><Citation>Y. Sotomi, P. Suwannasom, E. Tenekecioglu, et al., &#x201c;Differential Aspects Between Cobalt&#x2010;Chromium Everolimus Drug&#x2010;Eluting Stent and Absorb Everolimus Bioresorbable Vascular Scaffold: From Bench to Clinical Use,&#x201d; Expert Review of Cardiovascular Therapy 13, no. 10 (October 2015): 1127&#x2013;1145.</Citation></Reference><Reference><Citation>S. Kufner, M. Joner, A. Thannheimer, et al., &#x201c;Ten&#x2010;Year Clinical Outcomes From a Trial of Three Limus&#x2010;Eluting Stents With Different Polymer Coatings in Patients with Coronary Artery Disease: Results From the ISAR&#x2010;TEST 4 Randomized Trial,&#x201d; Circulation 139, no. 3 (January 2019): 325&#x2013;333.</Citation></Reference><Reference><Citation>T. Pilgrim, R. Piccolo, D. Heg, et al., &#x201c;Ultrathin&#x2010;Strut, Biodegradable&#x2010;Polymer, Sirolimus&#x2010;Eluting Stents Versus Thin&#x2010;Strut, Durable&#x2010;Polymer, Everolimus&#x2010;Eluting Stents for Percutaneous Coronary Revascularisation: 5&#x2010;Year Outcomes of the BIOSCIENCE Randomised Trial,&#x201d; Lancet 392, no. 10149 (September 2018): 737&#x2013;746.</Citation></Reference><Reference><Citation>M. G. Kong, J. K. Han, J. H. Kang, et al., &#x201c;Clinical Outcomes of Long Stenting in the Drug&#x2010;Eluting Stent Era: Patient&#x2010;Level Pooled Analysis From the GRAND&#x2010;DES Registry,&#x201d; EuroIntervention 16, no. 16 (March 2021): 1318&#x2013;1325.</Citation></Reference><Reference><Citation>F. J. Sawaya, T. Lef&#xe8;vre, B. Chevalier, et al., &#x201c;Contemporary Approach to Coronary Bifurcation Lesion Treatment,&#x201d; JACC: Cardiovascular Interventions 9, no. 18 (September 2016): 1861&#x2013;1878.</Citation></Reference><Reference><Citation>R. V. Jeger, S. Eccleshall, W. A. Wan Ahmad, et al., &#x201c;Drug&#x2010;Coated Balloons for Coronary Artery Disease,&#x201d; JACC: Cardiovascular Interventions 13, no. 12 (June 2020): 1391&#x2013;1402.</Citation></Reference><Reference><Citation>R. V. Jeger, A. Farah, M. A. Ohlow, et al., &#x201c;Long&#x2010;Term Efficacy and Safety of Drug&#x2010;Coated Balloons Versus Drug&#x2010;Eluting Stents for Small Coronary Artery Disease (Basket&#x2010;Small 2): 3&#x2010;Year Follow&#x2010;Up of a Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 396, no. 10261 (November 2020): 1504&#x2013;1510.</Citation></Reference><Reference><Citation>S. Y. Lee, Y. K. Cho, S. W. Kim, et al., &#x201c;Clinical Results of Drug&#x2010;Coated Balloon Treatment in a Large&#x2010;Scale Multicenter Korean Registry Study,&#x201d; Korean Circulation Journal 52, no. 6 (2022): 444.</Citation></Reference><Reference><Citation>C. Gobbi, F. Giangiacomi, I. Merinopoulos, et al., &#x201c;Drug Coated Balloon Angioplasty for De Novo Coronary Lesions in Large Vessels: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Scientific Reports 15, no. 1 (February 2025): 4921.</Citation></Reference><Reference><Citation>R. Caminiti, G. Vizzari, A. Ielasi, et al., &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Treating De Novo Large Vessel Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of 13 Studies Involving 2888 Patients,&#x201d; Clinical Research in Cardiology 114 (July 2024): 978&#x2013;990, https://doi.org/10.1007/s00392-024-02481-8.</Citation></Reference><Reference><Citation>J. L. Jiang, Q. J. Huang, and M. H. Chen, &#x201c;Efficacy and Safety of Drug&#x2010;Coated Balloon for De Novo Lesions of Large Coronary Arteries: Systematic Review and Meta&#x2010;Analysis of Randomized Controlled Trials,&#x201d; Heliyon 10, no. 3 (February 2024): e25264.</Citation></Reference><Reference><Citation>Z. Ma, K. Liu, Y. Hu, X. Hu, B. Wang, and Z. Li, &#x201c;Comparison Between Drug&#x2010;Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of RCT Data,&#x201d; Cardiovasc Drugs Ther [Internet] 39, no. 3 (January 2025): 677&#x2013;686, https://doi.org/10.1007/s10557-024-07548-2.</Citation></Reference><Reference><Citation>A. Abdel&#x2010;Salam and K. Eyres, &#x201c;Effects of Tourniquet During Total Knee Arthroplasty. A Prospective Randomised Study,&#x201d; Journal of Bone and Joint Surgery. British Volume 77&#x2013;B, no. 2 (March 1995): 250&#x2013;253.</Citation></Reference><Reference><Citation>J. J. Coughlan and A. Kastrati, &#x201c;Small Coronary Vessel Size: A Great Need for a Standardized Definition,&#x201d; Journal of the Society for Cardiovascular Angiography &amp; Interventions 1, no. 5 (September 2022): 100428.</Citation></Reference><Reference><Citation>X. F. Gao, X. Q. Kong, G. F. Zuo, Z. M. Wang, Z. Ge, and J. J. Zhang, &#x201c;Intravascular Ultrasound&#x2010;Guided Versus Angiography&#x2010;Guided Percutaneous Coronary Intervention: Evidence From Observational Studies and Randomized Controlled Trials,&#x201d; US Cardiology Review 14 (April 2020): e03.</Citation></Reference><Reference><Citation>L. Mauri, E. J. Orav, and R. E. Kuntz, &#x201c;Late Loss in Lumen Diameter and Binary Restenosis for Drug&#x2010;Eluting Stent Comparison,&#x201d; Circulation 111, no. 25 (June 2005): 3435&#x2013;3442.</Citation></Reference><Reference><Citation>T. Onishi, Y. Onishi, I. Kobayashi, and Y. Sato, &#x201c;Late Lumen Enlargement After Drug&#x2010;Coated Balloon Angioplasty for De Novo Coronary Artery Disease,&#x201d; Cardiovascular Intervention and Therapeutics 36, no. 3 (July 2021): 311&#x2013;318.</Citation></Reference><Reference><Citation>G. Zenunaj, L. Traina, P. Acciarri, et al., &#x201c;Primary Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Native Atherosclerotic Femoropopliteal Lesions: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Annals of Vascular Surgery 92 (May 2023): 294&#x2013;303.</Citation></Reference><Reference><Citation>J. A. C. Sterne, J. Savovi&#x107;, M. J. Page, et al., &#x201c;RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,&#x201d; BMJ 366 (August 2019): l4898.</Citation></Reference><Reference><Citation>A. Stang, &#x201c;Critical Evaluation of the Newcastle&#x2010;Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta&#x2010;Analyses,&#x201d; European Journal of Epidemiology 25, no. 9 (September 2010): 603&#x2013;605.</Citation></Reference><Reference><Citation>C. Gobbi, F. Giangiacomi, G. Pasero, et al., &#x201c;Efficacy and Safety of Sirolimus&#x2010;Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score&#x2010;Matched Study,&#x201d; Catheterization and Cardiovascular Interventions 105, no. 4 (March 2025): 861&#x2013;869.</Citation></Reference><Reference><Citation>C. Xingyou Cai, H. Xin Hong, W. Yuli Wang, Li Yafei Li, and Xu Guidong Xu, &#x201c;Drug&#x2010;Coated Balloon in the Treatment of Coronary Artery De&#x2010;Novo Large Lesionsangiography,&#x201d; Cellular and Molecular Biology 70, no. 4 (April 2024): 196&#x2013;201.</Citation></Reference><Reference><Citation>C. Gao, X. He, F. Ouyang, et al., &#x201c;Drug&#x2010;Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of Patients with De Novo Coronary Artery Lesions (REC&#x2010;CAGEFREE I): an Open&#x2010;Label, Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 404, no. 10457 (September 2024): 1040&#x2013;1050.</Citation></Reference><Reference><Citation>J. Goto, T. Niizeki, T. Iwayama, T. Sasaki, and M. Watanabe, &#x201c;One&#x2010;Year Outcome of Drug&#x2010;Coated Balloon Vs. Drug&#x2010;Eluting Stent in Patients Undergoing Initial Percutaneous Coronary Intervention (PCI) for De Novo Lesion,&#x201d; Cureus [Internet] 16, no. 3 (March 2024): e56346, https://www.cureus.com/articles/236464-one-year-outcome-of-drug-coated-balloon-vs-drug-eluting-stent-in-patients-undergoing-initial-percutaneous-coronary-intervention-pci-for-de-novo-lesion.</Citation></Reference><Reference><Citation>K. Zhao, Q. Guo, Z. Zhao, et al., &#x201c;Clinical Value of Drug&#x2010;Coated Balloon Versus Second&#x2010;Generation Drug&#x2010;Eluting Stent for De Novo Lesions in Large Coronary Arteries: Insights From the Real World,&#x201d; BMC Cardiovasc Disord [Internet] 24, no. 1 (December 2024): 697, https://doi.org/10.1186/s12872-024-04386-w.</Citation></Reference><Reference><Citation>I. Merinopoulos, T. Gunawardena, N. Corballis, et al., &#x201c;Assessment of Paclitaxel Drug&#x2010;Coated Balloon Only Angioplasty in STEMI,&#x201d; JACC: Cardiovascular Interventions 16, no. 7 (April 2023): 771&#x2013;779.</Citation></Reference><Reference><Citation>I. Merinopoulos, T. Gunawardena, N. Corballis, et al., &#x201c;Paclitaxel Drug&#x2010;Coated Balloon&#x2010;Only Angioplasty for De Novo Coronary Artery Disease in Elective Clinical Practice,&#x201d; Clinical Research in Cardiology 112, no. 9 (September 2023): 1186&#x2013;1193.</Citation></Reference><Reference><Citation>C. Li, X. Ding, L. Wang, et al., &#x201c;Feasibility and Safety of Drug&#x2010;Coated Balloon&#x2010;Only Angioplasty for De Novo Ostial Lesions of the Left Anterior Descending Artery: Two&#x2010;Center Retrospective Study,&#x201d; Front Cardiovasc Med [Internet] 9 (April 2022): 874394, https://doi.org/10.3389/fcvm.2022.874394/full.</Citation></Reference><Reference><Citation>R. V. Jeger, A. Farah, M. A. Ohlow, et al., &#x201c;Long&#x2010;Term Efficacy and Safety of Drug&#x2010;Coated Balloons Versus Drug&#x2010;Eluting Stents for Small Coronary Artery Disease (BASKET&#x2010;SMALL 2): 3&#x2010;Year Follow&#x2010;Up of a Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 396, no. 10261 (November 2020): 1504&#x2013;1510.</Citation></Reference><Reference><Citation>A. Farah, M. Elgarhy, M. A. Ohlow, et al., &#x201c;Efficacy and Safety of Drug&#x2010;Coated Balloons According to Coronary Vessel Size. A Report From the BASKET&#x2010;SMALL 2 Trial,&#x201d; Adv Interv Cardiol 18, no. 2 (2022): 122&#x2013;130.</Citation></Reference><Reference><Citation>H. Liu, Y. Zhao, Y. Lu, et al., &#x201c;The Drug Coated Balloon&#x2010;Only Strategy for Treatment of De Novo Left Main Coronary Artery Bifurcation Lesion: Stentless Strategy,&#x201d; Clinical and Applied Thrombosis/Hemostasis 28 (January 2022): 10760296221118489.</Citation></Reference><Reference><Citation>Z. Wang, Y. Yin, J. Li, et al., &#x201c;New Ultrasound&#x2010;Controlled Paclitaxel Releasing Balloon Vs. Asymmetric Drug&#x2010;Eluting Stent in Primary ST&#x2010;Segment Elevation Myocardial Infarction&#x2015;A Prospective Randomized Trial,&#x201d; Circulation Journal 86, no. 4 (March 2022): 642&#x2013;650.</Citation></Reference><Reference><Citation>X. Hao, D. Huang, Z. Wang, J. Zhang, H. Liu, and Y. Lu, &#x201c;Study on the Safety and Effectiveness of Drug&#x2010;Coated Balloons In Patients With Acute Myocardial Infarction,&#x201d; Journal of Cardiothoracic Surgery [Internet] 16, no. 1 (December 2021): 178, https://doi.org/10.1186/s13019-021-01525-8.</Citation></Reference><Reference><Citation>Y. Iwasaki, J. Koike, T. Ko, et al., &#x201c;Comparison of Drug&#x2010;Eluting Stents Vs. Drug&#x2010;Coated Balloon After Rotational Atherectomy for Severely Calcified Lesions of Nonsmall Vessels,&#x201d; Heart and Vessels 36, no. 2 (February 2021): 189&#x2013;199.</Citation></Reference><Reference><Citation>N. S. Vos, N. D. Fagel, G. Amoroso, et al., &#x201c;Paclitaxel&#x2010;Coated Balloon Angioplasty Versus Drug&#x2010;Eluting Stent in Acute Myocardial Infarction,&#x201d; JACC: Cardiovascular Interventions 12, no. 17 (September 2019): 1691&#x2013;1699.</Citation></Reference><Reference><Citation>N. Nishiyama, T. Komatsu, T. Kuroyanagi, et al., &#x201c;Clinical Value of Drug&#x2010;Coated Balloon Angioplasty for De Novo Lesions in Patients With Coronary Artery Disease,&#x201d; International Journal of Cardiology 222 (November 2016): 113&#x2013;118.</Citation></Reference><Reference><Citation>F. Nijhoff, P. Agostoni, A. Belkacemi, et al., &#x201c;Primary Percutaneous Coronary Intervention by Drug&#x2010;Eluting Balloon Angioplasty: The Nonrandomized Fourth Arm of the Deb&#x2010;Ami (Drug&#x2010;Eluting Balloon in St&#x2010;Segment Elevation Myocardial Infarction) Trial,&#x201d; supplement, Catheter Cardiovasc Interv [Internet] 86, no. S1 (October 2015): S34&#x2013;S44, https://doi.org/10.1002/ccd.26060.</Citation></Reference><Reference><Citation>L. Wang, X. Li, T. Li, L. Liu, H. Wang, and C. Wang, &#x201c;Novel Application of Drug&#x2010;Coated Balloons in Coronary Heart Disease: A Narrative Review,&#x201d; Frontiers in Cardiovascular Medicine 10 (March 2023): 1055274.</Citation></Reference><Reference><Citation>M. Lunardi, C. Zivelonghi, F. S. Van Den Brink, et al., &#x201c;Drug Eluting Balloon for the Treatment of Patients With Coronary Artery Disease: Current Perspectives,&#x201d; Cardiovascular Revascularization Medicine 19, no. 2 (March 2018): 215&#x2013;220.</Citation></Reference><Reference><Citation>S. P. Hoole and P. Bambrough, &#x201c;Recent Advances in Percutaneous Coronary Intervention,&#x201d; Heart 106, no. 18 (September 2020): 1380&#x2013;1386.</Citation></Reference><Reference><Citation>A. Habib and A. V. Finn, &#x201c;Endothelialization of Drug Eluting Stents and Its Impact on Dual Anti&#x2010;Platelet Therapy Duration,&#x201d; Pharmacological Research 93 (March 2015): 22&#x2013;27.</Citation></Reference><Reference><Citation>F. Kleber, D. Mathey, H. Rittger, and B. Scheller, &#x201c;How to Use the Drug&#x2010;Eluting Balloon: Recommendations by the German Consensus Group,&#x201d; EuroIntervention 7, no. K (May 2011): K125&#x2013;K128.</Citation></Reference><Reference><Citation>T. D. Gunawardena, N. Corballis, I. Merinopoulos, et al., &#x201c;Drug&#x2010;Coated Balloon Vs. Drug&#x2010;Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN&#x2010;LMS Study,&#x201d; Journal of Cardiovascular Development and Disease 10, no. 2 (February 2023): 84.</Citation></Reference><Reference><Citation>A. Y. Her, S. L. Yuan, E. J. Jun, et al., &#x201c;Drug&#x2010;Coated Balloon Treatment for Nonsmall De&#x2010;Novo Coronary Artery Disease: Angiographic and Clinical Outcomes,&#x201d; Coronary Artery Disease 32, no. 6 (September 2021): 534&#x2013;540.</Citation></Reference><Reference><Citation>Y. Lin, X. Sun, H. Liu, X. Pang, and S. Dong, &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Treating De Novo Coronary Lesions in Large Vessels: A Meta&#x2010;Analysis of Clinical Trials,&#x201d; Herz 46, no. 3 (June 2021): 269&#x2013;276.</Citation></Reference><Reference><Citation>Z. Ma, K. Liu, Y. Hu, X. Hu, B. Wang, and Z. Li, &#x201c;Comparison Between Drug&#x2010;Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of RCT Data,&#x201d; Cardiocasular Drugs and Therapy 39, (January 2025): 677&#x2013;686, https://doi.org/10.1007/s10557-024-07548-2.</Citation></Reference><Reference><Citation>R. W. Yeh, R. Shlofmitz, J. Moses, et al., &#x201c;Paclitaxel&#x2010;Coated Balloon Vs Uncoated Balloon for Coronary In&#x2010;Stent Restenosis: The AGENT IDE Randomized Clinical Trial,&#x201d; Journal of the American Medical Association 331, no. 12 (March 2024): 1015.</Citation></Reference><Reference><Citation>A. Latib, N. Ruparelia, A. Menozzi, et al., &#x201c;3&#x2010;Year Follow&#x2010;Up of the Balloon Elution and Late Loss Optimization Study (BELLO),&#x201d; JACC: Cardiovascular Interventions 8, no. 8 (July 2015): 1132&#x2013;1134.</Citation></Reference><Reference><Citation>B. Cortese, G. Di Palma, M. G. Guimaraes, et al., &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Small Coronary Vessel Disease,&#x201d; JACC: Cardiovascular Interventions 13, no. 24 (December 2020): 2840&#x2013;2849.</Citation></Reference><Reference><Citation>C. Yerasi, B. C. Case, B. J. Forrestal, et al., &#x201c;Risk of Mortality With Paclitaxel Drug&#x2010;Coated Balloon in De Novo Coronary Artery Disease,&#x201d; Cardiovascular Revascularization Medicine 21, no. 4 (April 2020): 549&#x2013;555.</Citation></Reference><Reference><Citation>T. Yamamoto, T. Ishii, and A. Ishida, &#x201c;Impact of Post Physiological Assessment After Treatment for De Novo Coronary Lesions Using Drug&#x2010;Coated Balloons,&#x201d; International Journal of Cardiology 363 (September 2022): 11&#x2013;19.</Citation></Reference><Reference><Citation>T. Asano, P. W. Serruys, C. Collet, et al., &#x201c;Angiographic Late Lumen Loss Revisited: Impact on Long&#x2010;Term Target Lesion Revascularization,&#x201d; European Heart Journal 39, no. 36 (September 2018): 3381&#x2013;3389.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>